Blood tests for Alzheimer disease markers in older hospitalized patients
Studies whether blood markers relate to memory decline and survival in hospitalized older adults.
Plain-language title generated from the registry record
Registry title: Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER)
Key facts
- Where
- Ancona, Fermo, and Messina, ItalySee the 3 sites
Where in Italy
- IRCCS INRCA HospitalAncona, ItalyTaking people
- IRCCS INRCA HospitalFermo, ItalyTaking people
- Policlinico UniversitarioMessina, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Istituto Nazionale di Ricovero e Cura per Anziani
- Trial code
- NCT07435467
- Record updated
- 27 February 2026
- Original description
The BAD-GER study is a multicenter, prospective, three-arm observational study serving to validate a prognostic biomarker algorithm for mortality and hospital readmission; this algorithm will be developed through the retrospective analysis of Alzheimer's Disease and neurodegeneration biomarkers in an already available discovery cohort of 700 previously hospitalized geriatric patients.Read full original descriptionShow less
Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER): a Multicenter, Observational, 3-arms, Prospective Study
The BAD-GER study is a multicenter, prospective, three-arm observational study serving to validate a prognostic biomarker algorithm for mortality and hospital readmission; this algorithm will be developed through the retrospective analysis of Alzheimer's Disease and neurodegeneration biomarkers in an already available discovery cohort of 700 previously hospitalized geriatric patients.
Inclusion: Inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis; inpatients with diagnosis of major neurocognitive disorder according to DSM-5 criteria (2013); inpatients with non-neurological diseases.
Exclusion: no informed consent; GROUP 2: Patients hospitalized for non-neurological diseases with dementia; Inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis; no informed consent; GROUP 3: Patients hospitalized for non-neurological diseases without dementia; inpatients with one of the following diagnoses: ischemic or hemorrhagic stroke, delirium, status epilepticus, encephalitis/meningitis; diagnosis of dementia; no informed consent.
GROUP 1: Patients hospitalized for acute neurological disorders.